152 related articles for article (PubMed ID: 3049266)
21. Chronic treatment of pathological hyperprolactinemia and acromegaly with the new ergot derivative terguride.
Dallabonzana D; Liuzzi A; Oppizzi G; Cozzi R; Verde G; Chiodini P; Rainer E; Dorow R; Horowski R
J Clin Endocrinol Metab; 1986 Oct; 63(4):1002-7. PubMed ID: 3745401
[TBL] [Abstract][Full Text] [Related]
22. [Arrest of lactation after 2nd trimester abortion with a single dose of cabergoline in comparison with 10-day administration of teguride].
Pavlista D; Calda P; Zivný J
Ceska Gynekol; 2003 Jan; 68(1):46-50. PubMed ID: 12708116
[TBL] [Abstract][Full Text] [Related]
23. Lisuride hydrogen maleate: evidence for a long lasting dopaminergic activity in humans.
Liuzzi A; Chiodini PG; Oppizzi G; Botalla L; Verde G; De Stefano L; Colussi G; Gräf KJ; Horowski R
J Clin Endocrinol Metab; 1978 Feb; 46(2):196-202. PubMed ID: 108287
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and pharmacodynamics of terguride following intramuscular administration in cows and goats.
Lapka R; Krejci P; Lidický J; Frühaufová M; Rezábek K
Acta Physiol Pol; 1989; 40(1):139-44. PubMed ID: 2603744
[TBL] [Abstract][Full Text] [Related]
25. Rapid regression of macroprolactinomas by the new dopamine partial agonist terguride.
Gräf KJ; Köhler D; Horowski R; Dorow R
Acta Endocrinol (Copenh); 1986 Apr; 111(4):460-6. PubMed ID: 3085417
[TBL] [Abstract][Full Text] [Related]
26. Cabergoline: a new drug for the treatment of hyperprolactinaemia.
Ferrari C; Piscitelli G; Crosignani PG
Hum Reprod; 1995 Jul; 10(7):1647-52. PubMed ID: 8582955
[TBL] [Abstract][Full Text] [Related]
27. The effect of lisuride hydrogen maleate in the hyperprolactinaemia-amenorrhoea syndrome: clinical and hormonal responses.
De Cecco L; Foglia G; Ragni N; Rossato P; Venturini PL
Clin Endocrinol (Oxf); 1978 Dec; 9(6):491-8. PubMed ID: 106990
[TBL] [Abstract][Full Text] [Related]
28. Effects of terguride in patients with Huntington's disease.
Stocchi F; Carta A; Berardelli A; Antonini A; Argenta M; Formica A; Agnoli A
Clin Neuropharmacol; 1989 Oct; 12(5):435-9. PubMed ID: 2575450
[TBL] [Abstract][Full Text] [Related]
29. Metergoline versus bromocriptine in the prevention of puerperal lactation. A double-blind clinical trial.
Scapin F; Buonaccorsi S; Tronconi G; Pellicciotta G; Pontiroli AE
Eur J Clin Pharmacol; 1982; 22(2):181-3. PubMed ID: 7047172
[TBL] [Abstract][Full Text] [Related]
30. Lisuride in parkinsonism.
Gopinathan G; Teräväinen H; Dambrosia JM; Ward CD; Sanes JN; Stuart WK; Evarts EV; Calne DB
Neurology; 1981 Apr; 31(4):371-6. PubMed ID: 7194429
[TBL] [Abstract][Full Text] [Related]
31. The effects of lisuride, terguride and bromocriptine on intraocular pressure (IOP).
Al-Sereiti MR; Turner P
Br J Clin Pharmacol; 1989 Feb; 27(2):159-63. PubMed ID: 2713211
[TBL] [Abstract][Full Text] [Related]
32. Effect of dihydroergocryptine on serum prolactin levels and milk secretion in puerperal women.
Nappi C; Colace G; Di Carlo C; Affinito P; Ruotolo C; Montemagno R; Farace MJ; Mailland F; Di Renzo GF
Gynecol Endocrinol; 1993 Jun; 7(2):129-33. PubMed ID: 8213227
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and endocrine effects of terguride in healthy subjects.
Krause W; Träger H; Kühne G; Sauerbrey N; Gräf KJ; Dorow R
Eur J Clin Pharmacol; 1990; 38(6):609-15. PubMed ID: 2373136
[TBL] [Abstract][Full Text] [Related]
34. Puerperal lactation inhibition with a novel 8 alpha-aminoergoline (CU 32-085).
Kvist Poulsen H; Rasmussen P; Riber Petersen M; Møller Pedersen S
Gynecol Obstet Invest; 1984; 17(3):139-44. PubMed ID: 6706248
[TBL] [Abstract][Full Text] [Related]
35. Effects of terguride on anterior pituitary function in parkinsonian patients treated with L-dopa: a double-blind study versus placebo.
Martignoni E; Horowski R; Liuzzi A; Costa A; Dallabonzana D; Cozzi R; Attanasio R; Rainer E; Nappi G
Clin Neuropharmacol; 1996 Feb; 19(1):72-80. PubMed ID: 8867520
[TBL] [Abstract][Full Text] [Related]
36. Suppression of puerperal lactation by metergoline.
Crosignani PG; Lombroso GC; Caccamo A; Reschini E; Peracchi M
Obstet Gynecol; 1978 Jan; 51(1):113-5. PubMed ID: 619329
[TBL] [Abstract][Full Text] [Related]
37. Lisuride treatment in Parkinson's disease: clinical and pharmacokinetic studies.
LeWitt PA; Burns RS; Calne DB
Adv Neurol; 1983; 37():131-40. PubMed ID: 6344586
[TBL] [Abstract][Full Text] [Related]
38. Effect of bromocriptine and chlorotrianisene on inhibition of lactation and serum prolactin. A comparative double-blind study.
Utian WH; Begg G; Vinik AI; Paul M; Shuman L
Br J Obstet Gynaecol; 1975 Sep; 82(9):755-9. PubMed ID: 1101946
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of puerperal lactation. A double blind study of bromocriptine and placebo.
Dewhurst CJ; Harrison RF; Biswas S
Acta Obstet Gynecol Scand; 1977; 56(4):327-31. PubMed ID: 341635
[TBL] [Abstract][Full Text] [Related]
40. Cabergoline versus bromocriptine in suppression of lactation after cesarean delivery.
Giorda G; de Vincentiis S; Motta T; Casazza S; Fadin M; D'Alberton A
Gynecol Obstet Invest; 1991; 31(2):93-6. PubMed ID: 2037265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
